Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the

Related Experiment Videos

Juan Manuel Sepúlveda-Sánchez1, Miguel Gil-Gil2, Miriam Alonso-García3

  • 1Medical Oncology Department, Hospital Universitario, 12 de Octubre, Avda. Andalucía s/n, 28041, Madrid, Spain. sepulvedasanchez@seom.org.

Targeted Oncology
|October 7, 2020
PubMed
Abstract

Insights

Palbociclib, a CDK4/6 inhibitor, showed limited efficacy in treating anaplastic oligodendroglioma (AO). Despite good tolerance, the drug did not improve progression-free survival in patients with recurrent AO.

Area of Science:

  • Neuro-oncology
  • Molecular oncology
  • Clinical trials

Background:

  • Anaplastic oligodendroglioma (AO) frequently exhibits alterations in the G1/S cell cycle checkpoint, involving cyclin-dependent kinase (CDK) 4 and retinoblastoma protein (pRb).
  • CDK4/6 inhibitors like palbociclib have demonstrated efficacy in breast cancer, suggesting potential for other malignancies.

Purpose of the Study:

  • To evaluate the efficacy and safety of palbociclib in patients with recurrent anaplastic oligodendroglioma.
  • To determine the progression-free survival at 6 months as the primary endpoint.

Main Methods:

  • A multicenter, open-label, phase II trial was conducted.
  • Patients with histologically and molecularly confirmed grade 3 oligodendroglioma, progression after standard therapy, and conserved pRb expression received palbociclib (125 mg/day, 3 weeks on/1 week off).

Main Results:

  • The study enrolled 34 patients and was stopped early due to lack of efficacy; 74% of evaluable patients progressed within 6 months.
  • Median progression-free survival was 2.8 months, and median overall survival was 32.1 months. No complete or partial responses were observed; 38% achieved stable disease.
  • Palbociclib was well tolerated, with neutropenia and thrombocytopenia being the most common adverse events, having no significant impact on treatment.

Conclusions:

  • Palbociclib monotherapy demonstrated unfavorable efficacy in recurrent anaplastic oligodendroglioma.
  • Despite good tolerability, palbociclib is not recommended as a treatment for this patient population based on this trial's findings.

Related Concept Videos